150025-93-7

Basic information

• Product Name: Benzenemethanamine, 3,4-dichloro-a-methyl-, (S)-
• Synonyms: Benzenemethanamine, 3,4-dichloro-a-methyl-, (S)-;Benzenemethanamine, 3,4-dichloro-α-methyl-, (αS)-;Benzenemethanamine, 3,4-dichloro-.alpha.-methyl-, (.alpha.S)-;(1R)-1-(3,4-dichlorophenyl)ethylaMine;(1S)-1-(3,4-DICHLOROPHENYL)ETHAN-1-AMINE;(S)-1-(3,4-Dichlorophenyl)ethanamine
• CAS NO: 150025-93-7
• Molecular Formula: C8H9Cl2N
• Molecular Weight: 190.07
• Product Categories: API intermediates
• Mol File: 150025-93-7.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: Benzenemethanamine, 3,4-dichloro-a-methyl-, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanamine, 3,4-dichloro-a-methyl-, (S)-(150025-93-7)
• EPA Substance Registry System: Benzenemethanamine, 3,4-dichloro-a-methyl-, (S)-(150025-93-7)

Safety Data

• Hazardous Substances Data: 150025-93-7(Hazardous Substances Data)

Usage

General Description

Benzenemethanamine, 3,4-dichloro-a-methyl-, (S)-, also known as Escitalopram, is a selective serotonin reuptake inhibitor (SSRI) used to treat depression and anxiety disorders. It works by increasing the levels of serotonin in the brain, which helps to improve mood, sleep, appetite, and energy levels. This chemical is the S-enantiomer of citalopram and is FDA approved for the treatment of major depressive disorder and generalized anxiety disorder. It is available in tablet and oral solution forms and is usually taken once daily. Common side effects may include drowsiness, dizziness, nausea, and dry mouth, and it may also increase the risk of suicidal thoughts and behaviors in some individuals, especially in the early stages of treatment.

Upstream product

• 2642-63-9 3',4'-dichloroacetophenone 
• 139752-39-9 1-(3,4-dichlorophenyl)ethanone oxime 

Downstream Products

• 2642-63-9 3',4'-dichloroacetophenone 
• 1624256-29-6 (R,S)-8-(1-(3,4-dichlorophenyl)ethyl)-1,3-dimethyl-6,7,8,9-tetrahydropyrazino[2,1-f]purine-2,4(1H,3H)-dione 
• 1395072-52-2 C₂₀H₂₁Cl₂N₇O 
• 1429176-22-6 C₁₈H₂₀Cl₂N₄O₂ 
• 1429176-23-7 (S)-3-(2-((S)-1-(3,4-dichlorophenyl)ethylamino)pyrimidin-4-yl)-4-isopropyloxazolidin-2-one 
• 1429176-38-4 C₂₁H₁₈Cl₂N₄O₂ 
• 1429176-39-5 C₂₁H₁₈Cl₂N₄O₂ 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS

The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a formula (I), or a pharmamceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

2-Mercaptoimidazoles, a new class of potent CCR2 antagonists

We describe the synthesis and SAR of a new class of CCR2 antagonists based on a 2-mercaptoimidazole scaffold. The initial lead 1a was optimized to the 3,4-disubstituted analogues 1p-(S) and 1q-(S), which have IC50 values in the MCP-1 induced Ca